SNOASNOAHealthcare · Drug Manufacturers - Specialty & Generic

SNOA Stock Forecast: Sonoma Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$0.72
−10.86% on the day

Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 21 of 100 as at 21 Nov 2026 — in the weakest quartile.

Market cap
$4.1M
Ticker Nerd rank
21/ 100
Median analyst target
—
Analysts covering
—
Revenue$6.4M+59.6% y/y
Operating income−$40K
Net income−$330K
Free cash flow−$651K
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−33.8%
1M
−37.2%
YTD
−80.2%
1Y
−77.9%
From 52W high
−81.0%
From 52W low
0.0%
$0.72
$3.80
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Sonoma Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
21/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
93
Quality
68
Revisions
20
Volatility
20
Momentum
18
Issuance
16
Accruals
14
Value
2

Growth (93): Sales and profits are climbing, and climbing faster than before.

Value (2): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

SNOA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on SNOA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.50$1.00$1.50$2.00$2.50$3.00$3.50$4.00Jan 26Apr 26Jul 26Oct 26SNOA

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

Recent analyst actionsNewest first
DateFirmActionRatingTarget
5 Sept 2023Ladenburg ThalmannInitiatesBuy$3.25
25 Nov 2020BenchmarkInitiatesSpeculative Buy—
25 Nov 2020Maxim GroupDowngradeHold—
6 Mar 2018Maxim GroupDowngradeHold—
28 Dec 2017BenchmarkInitiatesSpeculative Buy—
10 Nov 2017Maxim GroupMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

SNOA appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

SNOA vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Sonoma Pharmaceuticals, Inc. returned −77.9% against +6.9% for the S&P 500, dividends included.

SNOA vs S&P 500, last 12 monthsTotal return, rebased to 100
20406080100120Jan 26Apr 26Jul 26Oct 26SNOAS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

SNOA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
0.2×

Cheaper than 91% of US stocks

Price / book
0.6×

Cheaper than 83% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
40.2%

Higher than 50% of US stocks

Operating margin
−3.3%

Higher than 31% of US stocks

Net margin
−7.6%

Higher than 22% of US stocks

Returns & dividend
Return on equity
−34.5%

Higher than 26% of US stocks

Return on assets
−3.1%

Higher than 35% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Sonoma Pharmaceuticals, Inc. has a market value of $4.1M and an enterprise value of $91K.

  • Revenue in the twelve months to 30 June 2026: $21.9M. The latest quarter grew 59.6% year on year.

  • Net income over the same four quarters: −$2.3M, a −10.3% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$2.7M.

  • Shares outstanding: 4.8M.

  • Sonoma Pharmaceuticals, Inc. employs 10 people — $2.2M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

SNOA and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
SNOASonoma Pharmaceuticals, Inc.$4.1M21
YCBDcbdMD, Inc.$4.0M31
APUSApimeds Pharmaceuticals US, Inc.$3.0M11
GELSGelteq Ltd.$2.9M10
UPCUniverse Pharmaceuticals, Inc.$5.4M25
SBFMSunshine Biopharma, Inc.$1.8M34
SXTCChina Sxt Pharmaceuticals, Inc.$1.8M7

Take a look at SNOA’s peer groups, ranked by the model: healthcare stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Sonoma Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about SNOA

How does Ticker Nerd's model rank SNOA?

As at 21 Nov 2026, Sonoma Pharmaceuticals, Inc. ranks 21 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (93 of 100).

What is the SNOA stock forecast for 2030?

No analyst covering Sonoma Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SNOA are extrapolating price history, which says nothing about the business.

How has SNOA stock performed over the past year?

Sonoma Pharmaceuticals, Inc. returned -77.9% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Sonoma Pharmaceuticals, Inc. do?

Sonoma Pharmaceuticals Inc. is a healthcare company that develops and manufactures stabilized hypochlorous acid (HOCl) products used across wound care, eye care, oral and nasal care, dermatology, podiatry, animal health, and non-toxic disinfection. Its portfolio is built around topical and cleansing solutions designed for sensitive skin and tissue, supporting clinicians and patients in managing irritation, infection risk, and recovery in both medical and consumer settings.

Company

About Sonoma Pharmaceuticals, Inc.

Sonoma Pharmaceuticals Inc. is a healthcare company that develops and manufactures stabilized hypochlorous acid (HOCl) products used across wound care, eye care, oral and nasal care, dermatology, podiatry, animal health, and non-toxic disinfection. Its portfolio is built around topical and cleansing solutions designed for sensitive skin and tissue, supporting clinicians and patients in managing irritation, infection risk, and recovery in both medical and consumer settings. Sonoma Pharmaceuticals markets its products internationally through healthcare and specialty channels, with applications spanning acute and chronic care environments as well as veterinary uses. The company also focuses on advanced tissue care and other topical formulations, making it a niche participant in the broader pharmaceutical and medical products market. Sonoma Pharmaceuticals Inc. is headquartered in Boulder, Colorado.

CEO Ms. Amy M. Trombly Esq., J.D. · 10 employees · United States · https://sonomapharma.com